Rule 497(d)
FT 422
BIOTECHNOLOGY SELECT PORTFOLIO, SERIES 3
DIGITAL CONVERGENCE SELECT PORTFOLIO, SERIES 2
FIBER OPTICS SELECT PORTFOLIO, SERIES 2
GENOMICS & PROTEOMICS SELECT PORTFOLIO, SERIES 2
PHARMACEUTICAL SELECT PORTFOLIO, SERIES 3
STORAGE & NETWORKING SELECT PORTFOLIO SERIES
TECHNOLOGY SELECT PORTFOLIO, SERIES 3
BIOTECHNOLOGY PORTFOLIO, SERIES 3
DIGITAL CONVERGENCE PORTFOLIO, SERIES 2
FIBER OPTICS PORTFOLIO, SERIES 2
GENOMICS & PROTEOMICS PORTFOLIO, SERIES 2
PHARMACEUTICAL PORTFOLIO, SERIES 9
STORAGE & NETWORKING PORTFOLIO SERIES
TECHNOLOGY PORTFOLIO, SERIES 12
Supplement to the Prospectus dated March 22, 2000
Notwithstanding anything to the contrary in the Prospectus, Unit holders
who acquire Units of Genomics and Proteomics Portfolio, Series 2 which, as a
result of a reduction in the aggregate underlying value of the Securities, are
not subject to an initial sales charge will be subject to the maximum remaining
deferred sales charge (initially $.35 per Unit). In such case the maximum sales
charge may exceed 4.5% of the Public Offering Price per Unit, but in no event
will the maximum sales charge exceed 5.50% of the Public Offering Price per
Unit.
March 29, 2000
